Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective 4-1 BB agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
1. A method for treating cancer in a human patient comprising administering to said human patient a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a 4-1BB agonist, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO: 21 and SEQ ID NO: 22, respectively; wherein the 4-1BB agonist is a 4-1BB agonist monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO: 35 and SEQ ID NO: 36, respectively; and wherein the PD-1 antagonist is administered at a dose from 1.0 mg/kg to about 10 mg/kg, said 4-1BB agonist is administered at a dose from 0.6 mg/kg to 10.0 mg/kg and said PD-1 antagonist and said 4-1BB agonist are administered simultaneously or sequentially within about 30 minutes.
2. The method of claim 1 , wherein the PD-1 antagonist is administered at a separate time from the 4-1BB agonist.
3. The method of claim 1 , wherein the 4-1BB agonist is utomilumab.
4. The method of claim 1 , wherein the PD-1 antagonist is administered at a dose selected from the group consisting of 2 milligrams/kilogram (mg/kg) q2wk, 10 mg/kg q2wk, 1 mg/kg q3wk, 2 mg/kg q3wk, 3 mg/kg q3wk, 5 mg/kg q3wk, and 10 mg q3wk, and said 4-1BB agonist is utomilumab that is administered at a dose selected from the group consisting of 1.2 mg/kg q4wk, 2.4 mg/kg q4wk and 5.0 mg/kg q4wk.
5. The method of claim 1 , wherein the cancer is a solid tumor.
6. The method of claim 1 , wherein the cancer is advanced melanoma.
7. The method of claim 1 , wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).
8. The method of claim 1 , wherein the cancer is an advanced or metastatic solid tumor that tests positive for PD-L1 expression and is selected from the group consisting of: bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), and triple negative breast cancer.
9. The method of claim 1 , wherein the combination therapy is administered for at least 12 weeks.
10. The method of claim 9 , wherein the combination therapy comprises three 4 week cycles or four 3 week cycles.
11. The method of claim 1 , wherein said PD-1 antagonist and said 4-1BB agonist are administered at a dosage interval selected from the group consisting of 14 days (±2 days), 21 days (±2 days), and 30 days (1 2 days).